Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086983 · ClinicalTrials.gov registry record · Phase 1
Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00086983: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00086983 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00086983, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of rebeccamycin analog and oxaliplatin in treating patients with refractory solid tumors. Drugs used in chemotherapy, such as rebeccamycin analog and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells
Interventions
- DRUG oxaliplatin
- OTHER pharmacological study
- DRUG becatecarin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2004-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00086983
The ClinicalTrials.gov registry entry for NCT00086983 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which oxaliplatin is the first listed.
NCT00086983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00086983 about?
NCT00086983 is a clinical study titled "Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors". This phase I trial is studying the side effects and best dose of rebeccamycin analog and oxaliplatin in treating patients with refractory solid tumors. Drugs used in chemotherapy, such as rebeccamycin analog and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growi...
What is the current status of trial NCT00086983?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2004-05.
What interventions are being tested in trial NCT00086983?
The interventions under investigation include: oxaliplatin (DRUG), pharmacological study (OTHER), becatecarin (DRUG).
Who is sponsoring clinical trial NCT00086983?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.